Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
MDL 11939 is a potent, orally bioavailable, and selective antagonist of the serotonin (5-HT) receptor subtype 5-HT2A (Ki = 6.06 nM for the human receptor).1 It is selective for the human 5-HT2A receptor over human 5-HT2B and 5-HT2C and rat 5-HT2B receptors (Kis = 3,020, 1,020, and 4,700 nM, respectively), as well as 5-HT1, 5-HT1A, α1- and α2-adrenergic, dopamine D2, muscarinic acetylcholine, histamine, and opiate receptors.1,2 MDL 11939 administered to rats prior to or following learned helplessness-induced stress prevents increases in acoustic startle response.3 MDL 11939 (10 mg/kg, i.v.) also has anti-arrhythmic activity in anesthetized dogs following myocardial infarction.4
WARNING This product is not for human or veterinary use.
1. Pharmacological effects of MDL 11,939: A selective, centrally acting antagonist of 5-
2. Pharmacologic characterization of the human 5-
3. 5-
4. Antiarrhythmic and electrophysiologic effects of MDL 11,939, a novel class III antiarrhythmic agent in anesthetized dogs. J. Cardiovasc. Pharmacol. 16(3), 383-393 (1990).